SEC Form 4 · accession 0001758247-26-000004
Revolution Medicines, Inc. · RVMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elizabeth M Anderson
Director
Period of report
Sep 22, 2026
Accepted (ET)
Sep 24, 2026 · 6:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001628171
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 22, 2026 | M | 5,070 | $1.12 | A | 14,476 | D | |
| Common StockF2 | Sep 22, 2026 | S | 910 | $191.8521 | D | 13,566 | D | |
| Common StockF3 | Sep 22, 2026 | S | 4,985 | $192.5387 | D | 8,581 | D | |
| Common StockF4 | Sep 22, 2026 | S | 2,648 | $193.4392 | D | 5,933 | D | |
| Common StockF5 | Sep 22, 2026 | S | 1,500 | $194.5887 | D | 4,433 | D | |
| Common StockF6 | Sep 22, 2026 | S | 100 | $195.15 | D | 4,333 | D | |
| Common StockF7 | holding | — | — | — | 26,990 | I | See footnote | |
| Common StockF8 | holding | — | — | — | 15,000 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F9 | $1.12 | Sep 22, 2026 | M | 5,070 | D | — | Apr 19, 2028 | Common Stock | 6,165 | 1,095 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026.
- F2The transaction was executed in multiple trades at prices ranging from $191.65 to $191.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3The transaction was executed in multiple trades at prices ranging from $192.01 to $192.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4The transaction was executed in multiple trades at prices ranging from $193.00 to $193.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5The transaction was executed in multiple trades at prices ranging from $194.04 to $194.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6Includes 1,191 restricted stock units.
- F7Held by David W. Anderson 1996 Irrevocable Trust.
- F8Held by Irrevocable Deed of Trust of David W. Anderson and Elizabeth M. Anderson.
- F9Fully vested.